Epidemic response group to invest up to $384 mln in Novavax's COVID-19 vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Epidemic response group to invest up to $384 mln in Novavax's COVID-19 vaccine
May 12, 2020 8:19 AM EDT
Ladenburg Thalmann analyst Michael Higgins raised the price target on Novavax (NASDAQ: NVAX) to $38.00 (from $28.00) while maintaining a Buy rating.
The analyst commented, "Last night, Novavax announced its 1Q20 results, presenting a $0.58 loss per share, better than our estimate of -$0.77... More
May 11, 2020 5:26 PM EDT
Inovio Pharma (NASDAQ: INO) reported Q1 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $1.33 million versus the consensus estimate of $1.91 million.
INOVIO's President and Chief Executive Officer Dr. J. Joseph Kim said, "INOVIO had a very productive first quarter, laying the foundation for a... More
May 11, 2020 5:04 PM EDT
Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.58), $0.20 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $3.38 million versus the consensus estimate of $1.74 million.
Our accomplishments to-date in 2020, including significant progress in our influenza and COVID19 vaccine programs, are the most... More
